Monique Dail
About
Monique Dail is a scholar working on Hematology, Molecular Biology and Genetics.
According to data from OpenAlex, Monique Dail has authored 49 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 23 papers in Molecular Biology and 18 papers in Genetics. Recurrent topics in Monique Dail's work include Acute Myeloid Leukemia Research (33 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers). Monique Dail is often cited by papers focused on Acute Myeloid Leukemia Research (33 papers), Chronic Myeloid Leukemia Treatments (14 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers). Monique Dail collaborates with scholars based in United States, Canada and France. Monique Dail's co-authors include Elena B. Pasquale, Mitchell Koolpe, Brenda Chyla, Rosemary Burgess, Jalaja Potluri, Courtney D. DiNardo, Vinod Pullarkat, Christian Récher, Keith W. Pratz and Daniel A. Pollyea and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
In The Last Decade
Monique Dail
47 papers receiving 1.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Monique Dail United States | 21 | 890 | 843 | 275 | 264 | 255 | 49 | 1.5k | ||
| Rajani Kanteti United States | 21 | 168 0.2× | 761 0.9× | 128 0.5× | 513 1.9× | 51 0.2× | 40 | 1.4k | ||
| John Gooya United States | 16 | 197 0.2× | 448 0.5× | 144 0.5× | 237 0.9× | 65 0.3× | 25 | 779 | ||
| Trevor Price United States | 9 | 167 0.2× | 340 0.4× | 41 0.1× | 308 1.2× | 86 0.3× | 21 | 849 | ||
| Frank Breitenbuecher Germany | 18 | 811 0.9× | 728 0.9× | 22 0.1× | 278 1.1× | 393 1.5× | 33 | 1.5k | ||
| Francesca Pellicano United Kingdom | 17 | 570 0.6× | 458 0.5× | 31 0.1× | 157 0.6× | 352 1.4× | 27 | 992 | ||
| Sabrina Manni Italy | 19 | 217 0.2× | 626 0.7× | 37 0.1× | 197 0.7× | 177 0.7× | 43 | 907 | ||
| Cédric Leroy France | 13 | 192 0.2× | 524 0.6× | 71 0.3× | 255 1.0× | 143 0.6× | 20 | 871 | ||
| Valentina Pettirossi Italy | 13 | 191 0.2× | 444 0.5× | 34 0.1× | 126 0.5× | 194 0.8× | 19 | 680 | ||
| Nicole E. Carlson United States | 9 | 129 0.1× | 816 1.0× | 45 0.2× | 319 1.2× | 96 0.4× | 10 | 1.0k | ||
| Véronique Blanc France | 9 | 184 0.2× | 299 0.4× | 85 0.3× | 392 1.5× | 72 0.3× | 20 | 739 |
Countries citing papers authored by Monique Dail
Since
Specialization
Citations
This map shows the geographic impact of Monique Dail's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monique Dail with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monique Dail more than expected).
Fields of papers citing papers by Monique Dail
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Monique Dail. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monique Dail. The network helps show where Monique Dail may publish in the future.
Co-authorship network of co-authors of Monique Dail
This figure shows the co-authorship network connecting the top 25 collaborators of Monique Dail. A scholar is included among the top collaborators of Monique Dail based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monique Dail. Monique Dail is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bahlis, Nizar J., Rakesh Popat, Meral Beksaç, et al.. (2024). Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.. Journal of Clinical Oncology. 42(16_suppl). 7510–7510.
2.
Konopleva, Marina, Courtney D. DiNardo, Yan Sun, et al.. (2023). AML-095 Findings From an Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia (AML), Including AML-M4 and AML-M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza). Clinical Lymphoma Myeloma & Leukemia. 23. S266–S267.
3.
Hamidi, Habib, Diana Dunshee, Brian Higgins, Monique Dail, & Michael Boyiadzis. (2023). Clinico-Genomic Characterization of AML Patients Based on IL2RA (CD25) Expression Uncovers an Association with Stem Cell Signatures and FLT3-ITD Status and Informs Drug Combinations. Blood. 142(Supplement 1). 4329–4329.
4.
Daver, Naval, Alexander E. Perl, Joseph Maly, et al.. (2022). Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 40(35). 4048–4059.
5.
Konopleva, Marina, Michael J. Thirman, Keith W. Pratz, et al.. (2022). Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clinical Cancer Research. 28(13). 2744–2752.
6.
Pollyea, Daniel A., Keith W. Pratz, Andrew H. Wei, et al.. (2022). Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clinical Cancer Research. 28(24). 5272–5279.
7.
Prébet, Thomas, Aaron D. Goldberg, Joseph G. Jurcic, et al.. (2022). A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Leukemia & lymphoma. 63(9). 2180–2188.
8.
Schjesvold, Fredrik, Bruno Paiva, Vincent Ribrag, et al.. (2022). Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23(1). e59–e70.
9.
Abbas, Hussein A., Vakul Mohanty, Yuefan Huang, et al.. (2021). Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. Frontiers in Oncology. 11. 705627–705627.
10.
Pollyea, Daniel A., Courtney D. DiNardo, Martha Arellano, et al.. (2020). Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations. Blood. 136(Supplement 1). 5–7.
11.
Mali, Raghuveer Singh, Qi Zhang, RosaAnna DeFilippis, et al.. (2020). Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 106(4). 1034–1046.
12.
Gerds, Aaron T., Bart L. Scott, Peter L. Greenberg, et al.. (2018). PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis. Blood. 132(Supplement 1). 466–466.
13.
Yan, Mark, Judy Zhong, Kartik Krishnan, et al.. (2017). Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents. Blood. 130. 4241–4241.
14.
Akutagawa, Jon, Teng Huang, Tiffany Chang, et al.. (2016). Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras. Leukemia. 30(6). 1335–1343.
15.
Dail, Monique, Jason W.H. Wong, Jessica Lawrence, et al.. (2014). Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature. 513(7519). 512–516.
16.
Yang, Ming, Christopher C. Govern, Arup K. Chakraborty, et al.. (2012). Dysregulated RasGRP1 Responds to Cytokine Receptor Input in T Cell Leukemogenesis. DSpace@MIT (Massachusetts Institute of Technology).
17.
Sabnis, Amit J., Laurene S. Cheung, Monique Dail, et al.. (2009). Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells. PLoS Biology. 7(3). e1000059–e1000059.
18.
Koolpe, Mitchell, Rosemary Burgess, Monique Dail, & Elena B. Pasquale. (2005). EphB Receptor-binding Peptides Identified by Phage Display Enable Design of an Antagonist with Ephrin-like Affinity. Journal of Biological Chemistry. 280(17). 17301–17311.
19.
Dail, Monique, et al.. (2004). SHEP1 Function in Cell Migration Is Impaired by a Single Amino Acid Mutation That Disrupts Association with the Scaffolding Protein Cas but Not with Ras GTPases. Journal of Biological Chemistry. 279(40). 41892–41902.
20.
Koolpe, Mitchell, Monique Dail, & Elena B. Pasquale. (2002). An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor. Journal of Biological Chemistry. 277(49). 46974–46979.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Rajani Kanteti Breakdown of academic impact, for papers by John Gooya Breakdown of academic impact, for papers by Trevor Price Breakdown of academic impact, for papers by Frank Breitenbuecher Breakdown of academic impact, for papers by Francesca Pellicano Breakdown of academic impact, for papers by Sabrina Manni Breakdown of academic impact, for papers by Cédric Leroy Breakdown of academic impact, for papers by Valentina Pettirossi Breakdown of academic impact, for papers by Nicole E. Carlson Breakdown of academic impact, for papers by Véronique Blanc